Determine the necessary mass, volume, or concentration for preparing a solution.
≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at 2-8°C,Desiccated Ships Wet ice Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
FK706 is a potent, slow-binding and competitive inhibitor of human neutrophil elastase with an IC 50 of 83 nM and a K i of 4.2 nM. FK706 also inhibits mouse neutrophil elastase and porcine pancreatic elastase with IC 50 s of 22 nM and 100 nM, respectively, and has no inhibitory activity against other serine proteinases such as human pancreatic trypsin, human pancreatic α-chymotrypsin and human leukocyte cathepsin G. FK706 has anti-inflammatory effect
In Vitro
FK706 effectively inhibits the hydrolysis of bovine neck ligament elastin (2 mg/mL final concentration) by human neutrophil elastase (4 μg/mL final concentration) with an IC50 value of 230 nM. FK706 blocks the release of inflammatory chemokines, suppresses the expression of IL-8 and MCP-1 mRNA, and suppresses NF-κB activation. It seems possible that FK706 may directly blocks human lung fibroblasts activation of NF-κB, preventing expression of inflammatory chemokines during cigarette smoke–induced lung inflammation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
FK706 (10-100 mg/kg; subcutaneous injection; for 1-6 hours; male C57BL mice) treatment significantly suppresses human neutrophil elastase (20 μg/paw)-induced paw edema in mice in a dose-dependent manner (47% inhibition at a dose of 100 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male C57BL mice (6 weeks old) injected with human neutrophil elastase Dosage: 10 mg/kg, 32 mg/kg, 100 mg/kg Administration: Subcutaneous injection; for 1 hour, 2 hours, 4 hours, 6 hours Result: Significantly suppressed human neutrophil elastase-induced paw edema in mice in a dose-dependent manner.
Form:Solid
IC50& Target:IC50: 83 nM (Human neutrophil elastase), 22 nM (Mouse neutrophil elastase) and 100 nM (Porcine pancreatic elastase), ,Ki: 4.2 nM (Human neutrophil elastase)
| Canonical Smiles | CC(C)C(C(=O)C(F)(F)F)NC(=O)C1CCCN1C(=O)C(C(C)C)NC(=O)C2=CC=C(C=C2)C(=O)NCC(=O)[O-].[Na+] |
|---|---|
| IUPAC Name | sodium;2-[[4-[[(2S)-3-methyl-1-oxo-1-[(2S)-2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]carbamoyl]benzoyl]amino]acetate |
| InChIKey | DNTYCMNNMGACPR-JSAITXCESA-M |
| INCHI | 1S/C26H33F3N4O7.Na/c1-13(2)19(21(36)26(27,28)29)31-24(39)17-6-5-11-33(17)25(40)20(14(3)4)32-23(38)16-9-7-15(8-10-16)22(37)30-12-18(34)35;/h7-10,13-14,17,19-20H,5-6,11-12H2,1-4H3,(H,30,37)(H,31,39)(H,32,38)(H,34,35);/q;+1/p-1/t17-,19?,20-;/m0./s1 |
| Isomeric SMILES | CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)NC(C(C)C)C(=O)C(F)(F)F)NC(=O)C2=CC=C(C=C2)C(=O)NCC(=O)[O-].[Na+] |
| PubChem CID | 23690296 |
| MeSH Entry Terms | FK 706;FK706;sodium 2-(4-((1-((2-((3,3,3-trifluoro-1-isopropyl-2-oxopropyl)aminocarbonyl)pyrrolidin-1-yl)carbonyl)-2-methylpropyl)aminocarbonyl)benzoylamino)acetate |
| Molecular Weight | 592.54 |
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Peptides |
| Direct Parent | Dipeptides |
| Alternative Parents | Valine and derivatives Proline and derivatives Hippuric acids N-acyl-alpha amino acids Alpha amino acid amides Pyrrolidinecarboxamides Benzoyl derivatives N-acylpyrrolidines Tertiary carboxylic acid amides Alpha-haloketones Secondary carboxylic acid amides Carboxylic acid salts Monocarboxylic acids and derivatives Carboxylic acids Azacyclic compounds Organic metal halides Organic sodium salts Hydrocarbon derivatives Organic zwitterions Alkyl fluorides Organofluorides Organonitrogen compounds Organic oxides |
| Molecular Framework | Aromatic heteromonocyclic compounds |
| Substituents | Alpha-dipeptide - N-acyl-alpha-amino acid - N-acyl-alpha amino acid or derivatives - Valine or derivatives - Proline or derivatives - Hippuric acid - Hippuric acid or derivatives - Alpha-amino acid amide - Alpha-amino acid or derivatives - Benzamide - Benzoic acid or derivatives - N-acylpyrrolidine - Pyrrolidine carboxylic acid or derivatives - Benzoyl - Pyrrolidine-2-carboxamide - Monocyclic benzene moiety - Benzenoid - Pyrrolidine - Alpha-haloketone - Tertiary carboxylic acid amide - Secondary carboxylic acid amide - Carboxylic acid salt - Ketone - Carboxamide group - Monocarboxylic acid or derivatives - Organoheterocyclic compound - Carboxylic acid - Organic alkali metal salt - Azacycle - Organic metal halide - Alkyl fluoride - Organohalogen compound - Organofluoride - Organonitrogen compound - Organooxygen compound - Organic zwitterion - Carbonyl group - Organic salt - Organic sodium salt - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Organic nitrogen compound - Alkyl halide - Aromatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
| External Descriptors | Not available |
| Solubility | DMSO : 115 mg/mL (194.08 mM; Need ultrasonic) H2O : ≥ 100 mg/mL (168.76 mM) |
|---|